Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.

about

Arginase activity of Leishmania isolated from patients with cutaneous leishmaniasis.

P2860

Q46332681-4B8001F5-0F15-4AD1-9E9B-2DEA35C6233F

P2860

Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.

Item

http://www.wikidata.org/entity/Q39220191

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Cross-protective efficacy from ...... nst tegumentary leishmaniasis.

@en

Cross-protective efficacy from ...... nst tegumentary leishmaniasis.

@nl

type

Item

label

Cross-protective efficacy from ...... nst tegumentary leishmaniasis.

@en

Cross-protective efficacy from ...... nst tegumentary leishmaniasis.

@nl

prefLabel

Cross-protective efficacy from ...... nst tegumentary leishmaniasis.

@en

Cross-protective efficacy from ...... nst tegumentary leishmaniasis.

@nl

P1476

Cross-protective efficacy from ...... inst tegumentary leishmaniasis

@en

P2093

C A P Tavares

http://www.w3.org/2001/XMLSchema#string

D Menezes-Souza

http://www.w3.org/2001/XMLSchema#string

D P Lage

http://www.w3.org/2001/XMLSchema#string

E A F Coelho

http://www.w3.org/2001/XMLSchema#string

L E Costa

http://www.w3.org/2001/XMLSchema#string

M C Duarte

http://www.w3.org/2001/XMLSchema#string

V T Martins

http://www.w3.org/2001/XMLSchema#string

P2860

Leishmaniasis worldwide and global estimates of its incidence

Identification of proteins in promastigote and amastigote-like Leishmania using an immunoproteomic approach

DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

High-throughput analysis of synthetic peptides for the immunodiagnosis of canine visceral leishmaniasis

Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis

Antimony toxicity.

Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.

Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?

P304

108-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/PIM.12304

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bruno Mendes Roatt

Miguel A Chávez-Fumagalli

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290378891

http://www.w3.org/2001/XMLSchema#string

P698

26756314

http://www.w3.org/2001/XMLSchema#string

Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.

about

P2860

P2860

Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698